Connection

Andrew Kraft to Neoplasms

Back to Details
This is a "connection" page, showing publications Andrew Kraft has written about Neoplasms.
Andrew Kraft
Connection Strength
1.420
Neoplasms
  1. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species. Mol Cancer Ther. 2016 07; 15(7):1637-47.
    View in: PubMed
    Score: 0.245
  2. PIM kinase (and Akt) biology and signaling in tumors. Pharmacol Ther. 2015 Jul; 151:41-9.
    View in: PubMed
    Score: 0.225
  3. The BH3 mimetic ABT-737 induces cancer cell senescence. Cancer Res. 2011 Jan 15; 71(2):506-15.
    View in: PubMed
    Score: 0.167
  4. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem. 2008 Sep 05; 283(36):25003-13.
    View in: PubMed
    Score: 0.142
  5. Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy. Cancer Biol Ther. 2007 Jul; 6(7):1067-73.
    View in: PubMed
    Score: 0.132
  6. Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases inhibition of mTORC1 and promotes tumor growth. Proc Natl Acad Sci U S A. 2019 10 08; 116(41):20505-20510.
    View in: PubMed
    Score: 0.077
  7. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999 Jan 01; 85(1):178-87.
    View in: PubMed
    Score: 0.073
  8. Insulin receptor substrate 1 is a substrate of the Pim protein kinases. Oncotarget. 2016 Apr 12; 7(15):20152-65.
    View in: PubMed
    Score: 0.061
  9. Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors. Cancer Res. 2015 Dec 15; 75(24):5318-28.
    View in: PubMed
    Score: 0.059
  10. Inhibitors of cyclin-dependent kinase and cancer. J Mol Med (Berl). 1995 Oct; 73(10):509-14.
    View in: PubMed
    Score: 0.059
  11. Reducing CD73 expression by IL1?-Programmed Th17 cells improves immunotherapeutic control of tumors. Cancer Res. 2014 Nov 01; 74(21):6048-59.
    View in: PubMed
    Score: 0.054
  12. The 2014 Surgeon General's report: "The health consequences of smoking--50 years of progress": a paradigm shift in cancer care. Cancer. 2014 Jul 01; 120(13):1914-6.
    View in: PubMed
    Score: 0.053
  13. Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer. 2007 Dec 03; 7:221.
    View in: PubMed
    Score: 0.034
  14. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. Clin Cancer Res. 1999 Sep; 5(9):2344-8.
    View in: PubMed
    Score: 0.019
  15. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem. 2009 Jan 08; 52(1):74-86.
    View in: PubMed
    Score: 0.009
  16. Enolase isoenzymes as tumour markers. J Clin Chem Clin Biochem. 1986 Dec; 24(12):1009-16.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.